Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 25/100

ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Key Takeaway: Rosen Law Firm has initiated an investigation into ADMA Biologics, Inc. due to allegations of misleading business information that impacted investors. Following a report from short seller Culper Research claiming the company engaged in revenue inflation through channel stuffing, ADMA's stock experienced a substantial drop of 16.6%. The firm is preparing a class action lawsuit to pursue compensation for affected shareholders. Investors are encouraged to join the class action and seek legal counsel through Rosen Law Firm.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics stock fell 16.6% on March 24, 2026, indicating significant investor loss.
  • Allegations of misleading business information are damaging to company reputation.
  • The investigation by Rosen Law Firm suggests possible vulnerabilities in ADMA's financial practices.
  • The launch of a class action lawsuit may lead to further financial and legal complications for the company.

Full Press Release Details

NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) --
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=57940 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On March 24, 2026, Investing.com published an article entitled “ADMA Biologics shares plunge on short seller allegations.” The article stated that ADMA Biologics shares fell “after short seller Culper Research released a report alleging the company engaged in channel stuffing to inflate revenue growth.”
On this news, ADMA Biologics stock fell 16.6% on March 24, 2026.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
Toll Free: (866) 767-3653

Tags

Frequently Asked Questions

What is the purpose of the Rosen Law Firm's investigation?

The Rosen Law Firm is investigating potential securities claims for ADMA Biologics shareholders due to allegedly misleading business information.

How can investors join the class action against ADMA Biologics?

Investors can join the class action by visiting the Rosen Law Firm's website or calling Phillip Kim, Esq. at 866-767-3653.

What triggered the drop in ADMA Biologics' stock price?

ADMA Biologics' stock fell 16.6% on March 24, 2026, after allegations of channel stuffing were made by Culper Research.

Why choose the Rosen Law Firm for legal counsel?

The Rosen Law Firm has a proven track record in securities class actions and has recovered significant settlements for investors.

Are there any costs to join the class action?

Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement.

Last updated: Apr 24, 2026